multiple myeloma – Medxy AI

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

By MedXY 10/24/2025

Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Hematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Specialties

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

By MedXY 10/14/2025

A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therapeutic escalation strategies.

Hematology-Oncology Oncology Specialties

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

By MedXY 10/14/2025

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T therapy selection.

Hematology-Oncology news Oncology

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY 10/14/2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal residual disease outcomes.

Hematology-Oncology news Oncology

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

By MedXY 10/14/2025

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.

Clinical Updates Hematology-Oncology Specialties

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

By MedXY 09/09/2025

A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring the need for targeted therapeutic strategies.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY 08/30/2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

$Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma$

Clinical Updates Hematology-Oncology Specialties

Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

By MedXY 08/29/2025

FCARH143, a fully human BCMA-directed CAR-T cell therapy, shows remarkable long-term efficacy and manageable safety profile in heavily pretreated relapsed/refractory multiple myeloma patients over 5 years.

Allergy & Immunology Hematology-Oncology Specialties

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

By MedXY 08/29/2025

Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for prophylactic strategies.

$Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study$

Hematology-Oncology Specialties

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study

By MedXY 08/29/2025

This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.

Clinical Updates news

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols

By MedXY 08/23/2025

A secondary analysis of three total therapy clinical trials reveals significant long-term survival improvements in multiple myeloma patients with modern combinational and stem cell transplant approaches incorporating immunomodulatory and proteasome inhibitors.

$Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial$

Clinical Updates Hematology-Oncology news Specialties

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

By MedXY 08/07/2025

The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.

Clinical Updates Hematology-Oncology news Specialties

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY 08/07/2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

$Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial$

Clinical Updates Hematology-Oncology news Specialties

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

By MedXY 08/07/2025

Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial

By MedXY 08/07/2025

KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.

Clinical Updates Hematology-Oncology news Specialties

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights$

Clinical Updates Hematology-Oncology news Specialties

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY 08/02/2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.